Why Semaglutide Got So Hard to Find

A couple of years ago semaglutide seemed to be everywhere: med spas, telehealth apps, compounding pharmacies and research-peptide sites. Since then the market has narrowed fast. Here’s what changed, and why so many sources have gone quiet.

What semaglutide is

Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk. It’s FDA-approved and sold by prescription as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management, including a pill version of Wegovy.

The shortage ended

While semaglutide was on the FDA’s drug shortage list, pharmacies were allowed to compound copies of it. On February 21, 2025, the FDA declared the shortage over and gave compounders a short wind-down: until April 22, 2025 for pharmacies and May 22, 2025 for outsourcing facilities. After that, mass-producing copies of an approved drug was no longer allowed.

Wave after wave of warning letters

On September 16, 2025, the FDA published more than 55 warning letters to online sellers of compounded GLP-1 drugs over how they were marketed. In February 2026 it announced it would restrict the GLP-1 active ingredients that feed non-approved compounded products and go after misleading ads, and it followed with about 30 more letters to telehealth companies in February and March 2026.

Novo Nordisk in court

Novo Nordisk has filed a long run of lawsuits against compounders and resellers. In February 2026 it sued Hims & Hers over its compounded semaglutide; the two settled in March 2026, with Hims agreeing to stop advertising compounded GLP-1 drugs.

What regulators are actually targeting

The FDA’s recent warning letters to online peptide sellers, including a round on August 24, 2026, focused on websites marketing compounds for people: dosing charts, injection guides, weight-loss and before-and-after claims. That’s the line that matters. A research supplier sells to researchers, publishes a batch-specific Certificate of Analysis for every lot, and gives no dosing or human-use advice. Sellers that blur that line are the ones disappearing.

The payment squeeze

Payment access is the weak point for anyone selling peptides online. Card processors treat the whole category as high risk: Stripe lists peptides as a restricted business, and most processors simply refuse them. When drug makers and regulators turn up the pressure, processors and platforms are usually the first to act, and sellers that lose payment access tend to disappear within weeks.

That’s why so many listings vanish, change names or move to crypto-only and payment-app checkouts.

What it means if you’re looking

• Expect fewer, less stable sources. Sellers come and go, rename products or switch to payment methods with fewer protections.
• Counterfeit risk rises when supply shrinks. An independent, batch-specific Certificate of Analysis (identity by mass spectrometry, purity by HPLC) matters more than ever. A COA you can’t match to the batch you received isn’t proof of anything.
• Semaglutide is a prescription medicine. Anyone interested in it as a treatment should talk to a licensed medical provider about the prescription options that exist today.

Sources

• NCPA: Semaglutide shortage is over, FDA says (Feb 25, 2025)
• Spencer Fane: Beyond the headlines, FDA warning letters to GLP-1 compounders
• Polsinelli: FDA threatens escalating enforcement on GLP-1 compounding (Feb 2026)
• Fierce Pharma: FDA ramps up crackdown with 30 more warning letters (2026)
• Frier Levitt: FDA warning letters and the Hims–Novo Nordisk deal
• FDA: Warning letters (public database)
• Stripe: Prohibited and restricted businesses

For the bigger picture on payments, see why payment processors avoid research peptides.

This article summarizes public reporting and regulatory actions. It is general information, not legal or medical advice, and nothing here is dosing or human-use guidance.